Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PUMA BIOTECHNOLOGY, INC.

(PBYI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Puma Biotechnology Gets 5-Year Extension for Key Nerlynx Patent

11/23/2021 | 04:27pm EST


ę MT Newswires 2021
All news about PUMA BIOTECHNOLOGY, INC.
01/20Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
01/12Puma Biotechnology's NERLYNX« Included in Two Important NCCN Clinical Practice Guidelin..
BU
01/12Puma Biotechnology’s NERLYNX« Included in Two Important NCCN Clinical Practice Gui..
CI
01/10PUMA BIOTECHNOLOGY, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
01/10Puma Biotechnology Releases Updated Corporate Presentation
BU
01/04Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference
BU
2021Puma Biotechnology, Inc Announces Resignation of Ann Miller as Its Director, Effective ..
CI
2021PUMA BIOTECHNOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Puma Biotechnology Shares Breast Cancer Trial Data
MT
2021Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meet..
BU
More news
Analyst Recommendations on PUMA BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 245 M - -
Net income 2021 -39,3 M - -
Net cash 2021 25,0 M - -
P/E ratio 2021 -2,65x
Yield 2021 -
Capitalization 95,3 M 95,3 M -
EV / Sales 2021 0,29x
EV / Sales 2022 0,35x
Nbr of Employees 267
Free-Float 86,7%
Chart PUMA BIOTECHNOLOGY, INC.
Duration : Period :
Puma Biotechnology, Inc. Technical Analysis Chart | PBYI | US74587V1070 | MarketScreener
Technical analysis trends PUMA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 2,33 $
Average target price 7,83 $
Spread / Average Target 236%
EPS Revisions
Managers and Directors
Alan H. Auerbach Founder
Maximo F. Nougues Chief Financial Officer
Jay M. Moyes Lead Independent Director
Troy E. Wilson Independent Director
Adrian M. Senderowicz Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PUMA BIOTECHNOLOGY, INC.-17.43%95
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601